Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance

Area of Science:

• Neuro-oncology
• Cancer Biology
• Epigenetics

Background:

• Glioblastoma (GBM) is an aggressive brain tumor driven by stem-like cancer cells (GSCs) resistant to therapy.
• Understanding GSC proliferation and drug resistance mechanisms is crucial for developing effective treatments.

Purpose of the Study:

• To investigate the adaptive mechanisms of GSCs in response to targeted kinase inhibitors.
• To identify molecular pathways involved in GSC persistence and drug tolerance.

Main Methods:

• Analysis of GSC transitions to a slow-cycling state under kinase inhibitor treatment.
• Investigation of Notch signaling pathway activation and histone methylation changes in persister GSCs.
• Assessment of KDM6A/B histone demethylase expression and dependency in slow-cycling GSCs.
• Examination of slow-cycling cells in primary glioblastomas.

Main Results:

• Glioblastoma stem cells reversibly transition to a slow-cycling, persistent state when exposed to kinase inhibitors.
• This persistent state involves upregulation of primitive developmental programs and dependence on Notch signaling.
• The transition is associated with significant redistribution of repressive histone methylation.
• Persister GSCs upregulate and depend on histone demethylases KDM6A/B.
• Slow-cycling cells with high Notch activity and histone demethylase expression are found in untreated primary glioblastomas.

Conclusions:

• Cancer cells can co-opt developmental programs for adaptation and survival under therapeutic pressure.
• Targeting epigenetic modifiers (KDM6A/B) and developmental pathways (Notch) offers potential strategies to eliminate refractory glioblastoma cells.
• Identifying pre-existing slow-cycling cells in tumors may predict relapse risk.